Genentech, a member of the Roche Group, has broken ground on its newest U.S. manufacturing site in Holly Springs, North Carolina—its first manufacturing facility on the East Coast. Genentech’s initial investment in North Carolina is estimated at more than $700 million and is part of Roche’s $50 billion commitment to invest in U.S. manufacturing infrastructure and R&D. The 65,000 m² facility is strategically designed to support production of the company’s future portfolio of metabolic medi...